Over the past two years, the global in-vitro diagnostics (IVD) sector has experienced various shifts and developments. The pandemic’s far-reaching impact across economies and healthcare systems has affected everything from IVD testing trends, to laboratory capacities. As covid-19 becomes endemic, IVD companies are reassessing their priorities based on future growth opportunities and challenges.

China’s government is investing to build up the country’s in vitro diagnostics (IVD) testing capacity and meet strong clinical demand from an ageing population. With major policies and the growth of domestic players shaking up the country’s IVD market dynamics, companies are localising and adapting their strategies to stay ahead in this fast-evolving market. 

Asia-Pacific (APAC) IVD markets have grown and exceeded their pre-pandemic size in 2019. This growth is largely due to covid-19 testing.

China Segmentation Surgical Devices Tracker is the go-to source of data, analysis and forecasts for the world’s largest emerging surgical device market at city-tier and hospital-class levels.

Clearstate’s IVD Gateway solution delivers precise, credible and granular market data with global forecasts.

y6trhththh

Monitor top IVD companies’ market performance and business activity in China on a quarterly basis with Clearstate’s Quarterly Company Insights solution

Most-commonly tested cancer biomarkers using NGS in Europe: RAS, BRAF, EGFR
With more precision oncology treatments introduced in the market, and a growing number of actionable biomarkers, next-generation sequencing (NGS) is becoming increasingly important in detecting multiple mutations and biomarkers.

Larger gene panels are the predominant NGS testing strategy in EU5

The growing number of biomarkers for which oncologists need information for treatment decision-making has necessitated a shift toward more comprehensive genomic profiling through next-generation sequencing (NGS).

Precision medicine and access to NGS cancer biomarker testing in Europe

Advancements in cancer biomarker testing through the use of powerful molecular testing technologies such as next-generation sequencing (NGS) is supporting the use of precision medicine. 

Proportion of cancer biomarker testing done with NGS expected to double in 2022 compared to 2019

Across Europe, there are varying levels of laboratory infrastructure capacity supporting NGS testing and integration of NGS testing in cancer care.

Next-generation sequencing (NGS) in cancer biomarker testing: Testing trends in Europe labs

Europe’s cancer burden is increasing, with more patients undergoing biomarker testing in order to access more targeted and effective therapies. Economist Intelligence
Clearstate expects the number of patients undergoing routine molecular testing for cancer biomarkers tracked by IVD Gateway to grow at an average annual rate between 6.2 to 19.2% in EU5 countries from 2020 to 2025.